A candidate drug must be shown to be both potent and non-toxic in relevant models. While early early screening in murine models is enough to begin a program, the demands for data from larger models is increasing. Traditionally, process development for nanomedicine production at an intermediate scale is a barrier to this work. However, with NxGen technology on the NanoAssemblr Blaze, these important studies can be conducted efficiently with a process that mirrors a clinical scale implementation.
NxGen Technology delivers a scalable means to perform the critical particle formation step in a nanomedicine development process. However, success of a program requires a scalable, end-to-end process. Using the NanoAssemblr Blaze, process development can be conducted on both the upstream and downstream portions, from material preparation to buffer exchange, filtering and analytics, to ensure that a program is ready to quickly accelerate to the clinic.